Conventional influenza vaccines are designed to stimulate neutralizing antibodies against immunodominant but highly variable hemagglutinin antigens. Inherent limitations include suboptimal protection against rapidly changing seasonal influenza viruses and a lack of protection against antigenically novel pandemic influenza. New technologies for developing influenza vaccines that induce more broadly protective and durable immunity are a growing area of research and focus on a variety of approaches, including targeting conserved antigens and stimulating cross-reactive T cell responses. This review highlights a new effort to track the development of universal influenza vaccine technologies. The Universal Influenza Vaccine Technology Landscape is intended to provide stakeholders and funders with a common source of information to monitor research progress and identify opportunities for informed investments and collaboration.
Bibliographical noteFunding Information:
This work was supported by the Task Force for Global Health , under contract with the University of Minnesota . All authors participate in the Universal Influenza Vaccine Technology Landscape working group and all contributed to this review. The opinions expressed in this review do not necessarily reflect the views of the organizations with which the authors are affiliated.
Neutrality and transparency are critical features of the landscape. The Task Force for Global Health, which established the Consortium with funding from the Bill and Melinda Gates Foundation, provides financial support to CIDRAP for the project. As an academic unit operating independently within the University of Minnesota, with no conflicts of interest regarding any influenza vaccine R&D activities or outcomes, CIDRAP serves as a neutral platform for gathering and analyzing influenza vaccine data for the landscape. In addition, a small working group was established for the project to provide critical review and subject-matter expertise in influenza vaccine R&D and vaccine database development. The working group includes representatives from the Task Force for Global Health, WHO, NIAID, the PATH Center for Vaccine Innovation and Access, the European Commission, and the US Biomedical Advanced Research and Development Authority (BARDA).
© 2020 Elsevier B.V.
PubMed: MeSH publication types
- Journal Article
- Research Support, Non-U.S. Gov't